Veracyte (VCYT) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free VCYT Stock Alerts $20.16 -0.49 (-2.37%) (As of 02:30 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 9 at 11:24 AM | marketbeat.comSeven Eight Capital LP Purchases Shares of 40,641 Veracyte, Inc. (NASDAQ:VCYT)Seven Eight Capital LP purchased a new stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 40,641 shares of the biotechnology company's stock, valued at approximately $1,118,000. SevJune 9 at 1:42 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by BrokeragesJune 8 at 5:38 AM | marketbeat.comRafferty Asset Management LLC Sells 52,956 Shares of Veracyte, Inc. (NASDAQ:VCYT)Rafferty Asset Management LLC lowered its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 24.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 159,465 shares of the biotechnology company's stock afteJune 5, 2024 | marketbeat.com406,749 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Norges BankNorges Bank bought a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 406,749 shares of the biotechnology company's stock, valued at approximately $June 3, 2024 | marketbeat.comCampbell & CO Investment Adviser LLC Invests $2.72 Million in Veracyte, Inc. (NASDAQ:VCYT)Campbell & CO Investment Adviser LLC bought a new stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 98,696 shares of the biotechnology companyJune 2, 2024 | americanbankingnews.comInsider Selling: Veracyte, Inc. (NASDAQ:VCYT) Director Sells $32,319.00 in StockMay 31, 2024 | insidertrades.comMuna Bhanji Sells 1,539 Shares of Veracyte, Inc. (NASDAQ:VCYT) StockMay 31, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Trexquant Investment LPTrexquant Investment LP lessened its stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 69.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,363 shares of the biotechnology company's stock after selling 73,798May 28, 2024 | finance.yahoo.comVeracyte (VCYT) Fell Due to a Lack of Rising ProfitabilityMay 28, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Artisan Partners Limited PartnershipArtisan Partners Limited Partnership trimmed its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 5.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,217,728 shares of the biotechnology company'May 23, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Dimensional Fund Advisors LPDimensional Fund Advisors LP raised its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 5.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,372,703 shares of the biotechMay 22, 2024 | businesswire.comVeracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and CancerMay 21, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Purchased by GW&K Investment Management LLCGW&K Investment Management LLC boosted its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 14.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,415,237 shares of the biotechnology company's stock afterMay 17, 2024 | marketbeat.comNikko Asset Management Americas Inc. Sells 68,900 Shares of Veracyte, Inc. (NASDAQ:VCYT)Nikko Asset Management Americas Inc. decreased its stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,104,676 shares of the biotechnology company's stocMay 15, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Bought by Russell Investments Group Ltd.Russell Investments Group Ltd. boosted its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 102.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,808 shares of the biotechnology compaMay 12, 2024 | marketbeat.comEssex Investment Management Co. LLC Has $3.11 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)Essex Investment Management Co. LLC lessened its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 35.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 112,934 shares of the biotechnology company's stock after selling 62,815 sMay 10, 2024 | markets.businessinsider.comVeracyte’s Robust Performance and Growth Potential Reinforce Buy RatingMay 10, 2024 | markets.businessinsider.comVeracyte’s Strong Q1 Performance and Upbeat Outlook Justify Buy RatingMay 9, 2024 | finance.yahoo.comIs Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?May 8, 2024 | markets.businessinsider.comMaintaining Buy on Veracyte: Strong Q1 Performance and Progress Toward ProfitabilityMay 8, 2024 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comNeedham & Company LLC Cuts Veracyte (NASDAQ:VCYT) Price Target to $27.00Needham & Company LLC cut their price target on Veracyte from $33.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday.May 8, 2024 | marketbeat.comVeracyte (NASDAQ:VCYT) Posts Earnings ResultsVeracyte (NASDAQ:VCYT - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.17. Veracyte had a negative return on equity of 2.02% and a negative net margin of 20.61%. The company had revenue of $96.84 million during the quarter, compared to analysts' expectations of $93.35 million. During the same quarter in the prior year, the business posted ($0.11) earnings per share. The company's revenue for the quarter was up 17.5% compared to the same quarter last year.May 8, 2024 | finance.yahoo.comVeracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ...May 7, 2024 | finance.yahoo.comVeracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test PerformanceMay 7, 2024 | seekingalpha.comVeracyte, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | businesswire.comVeracyte Announces First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comHere's what to expect from Veracyte's earningsMay 6, 2024 | businesswire.com14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease UnderstandingMay 5, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Fisher Asset Management LLCFisher Asset Management LLC cut its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 13.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 874,471 shares of the biotechnology company's stock after selling 130,958 shareMay 4, 2024 | marketbeat.comVestmark Advisory Solutions Inc. Acquires New Holdings in Veracyte, Inc. (NASDAQ:VCYT)Vestmark Advisory Solutions Inc. acquired a new stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 176,315 shares of tApril 27, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by New York State Common Retirement FundNew York State Common Retirement Fund trimmed its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 837,467 shares of the biotechnology company's stoApril 26, 2024 | bizjournals.comDiagnostics pioneer Bonnie Anderson launches PinkDx to focus on women's healthApril 25, 2024 | marketbeat.comSemanteon Capital Management LP Makes New $1.24 Million Investment in Veracyte, Inc. (NASDAQ:VCYT)Semanteon Capital Management LP acquired a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 44,989 shares of the biotechnology company'April 22, 2024 | businesswire.comVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024April 22, 2024 | finance.yahoo.comNew Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 22, 2024 | businesswire.comNew Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 18, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Cuts Position in Veracyte, Inc. (NASDAQ:VCYT)Sumitomo Mitsui Trust Holdings Inc. cut its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 2.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,104,676 shares of the biotechnology company's stock after selling 68,900 shares durinApril 17, 2024 | finance.yahoo.comVeracyte, Inc. (VCYT)April 16, 2024 | businesswire.comVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024April 15, 2024 | marketbeat.comVeracyte (NASDAQ:VCYT) Sets New 1-Year Low on Analyst DowngradeVeracyte (NASDAQ:VCYT) Hits New 52-Week Low After Analyst DowngradeApril 15, 2024 | marketbeat.comThe Goldman Sachs Group Cuts Veracyte (NASDAQ:VCYT) Price Target to $28.00The Goldman Sachs Group decreased their price target on shares of Veracyte from $32.00 to $28.00 and set a "buy" rating on the stock in a report on Monday.April 14, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Sells 251,865 Shares of Veracyte, Inc. (NASDAQ:VCYT)Mirae Asset Global Investments Co. Ltd. lowered its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 47.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 280,062 shares of the bApril 13, 2024 | marketbeat.comShort Interest in Veracyte, Inc. (NASDAQ:VCYT) Increases By 32.8%Veracyte, Inc. (NASDAQ:VCYT - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 3,640,000 shares, an increase of 32.8% from the March 15th total of 2,740,000 shares. Based on an average daily trading volume, of 633,600 shares, the short-interest ratio is currently 5.7 days.April 9, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Stock Holdings Reduced by Assenagon Asset Management S.A.Assenagon Asset Management S.A. lowered its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 80.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,943 shares of the biotechnologyApril 3, 2024 | insidertrades.comVeracyte, Inc. (NASDAQ:VCYT) Director Karin Eastham Sells 10,000 SharesApril 2, 2024 | finance.yahoo.comWhat Makes Veracyte (VCYT) a Lucrative Investment?March 28, 2024 | marketbeat.comARK Investment Management LLC Acquires 62,011 Shares of Veracyte, Inc. (NASDAQ:VCYT)ARK Investment Management LLC raised its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,655,603 shares of the biotechnology company's stock after buying anMarch 20, 2024 | marketbeat.comAEGON ASSET MANAGEMENT UK Plc Makes New $9.59 Million Investment in Veracyte, Inc. (NASDAQ:VCYT)AEGON ASSET MANAGEMENT UK Plc bought a new position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 348,463 shares of the biotechnology company's stock, valued at approximately $9,586,000. AEGOMarch 17, 2024 | marketbeat.comWellington Management Group LLP Has $157.83 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)Wellington Management Group LLP cut its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,067,864 shares of the biotechnology company Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address Options expert shares his top option strategy for free (Ad)A 35 year old man from central Florida has stumbled on one of the best strategies we’ve seen in a long time. For the last 30 months his “Friday to Monday” trading strategy has maintained a 71% win rate on more than 350 trades. That includes multiple big time winners like 82% from Adobe… 77% from Palo Alto… But also a barrage of smaller winners like 20% from AMC… Each of which were opened on a Friday afternoon and closed the very next Monday morning. As you’ll see in his brand new video, this strange strategy has given him the ability to capture big time market moves over the weekend. Check it out, simply follow this link here. VCYT Media Mentions By Week VCYT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VCYT News Sentiment▼1.580.76▲Average Medical News Sentiment VCYT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VCYT Articles This Week▼43▲VCYT Articles Average Week Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Genetron News Today RadNet News Today Guardant Health News Today Fortrea News Today CareDx News Today Viridian Therapeutics News Today Castle Biosciences News Today Fulgent Genetics News Today Celcuity News Today Sera Prognostics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VCYT) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored